Lima, December 30, 2021Updated 12/30/2021 12:32 pm
People vaccinated with two doses of Johnson & Johnson (J&J) may be 85% protected from needing hospitalization after contracting COVID-19 with the omicron variant, according to a study conducted in South Africa, details of which were revealed today.
The research was conducted on a sample of 69,092 healthcare workers who were given a booster injection of NOT A WORD (the same formula they had already received for their first dose) between November 15 and December 20.
On those dates, South Africa was going through its fourth great wave of COVID-19, driven by the variant omicron.
In particular, the researchers observed that efficacy against hospitalization stood at 63% shortly after the second inoculation and that protection “grew over time”, reaching 84% after two weeks and by 85% from one month after the reinforcement.
The study, which counts the renowned researcher Linda-Gail Bekker among its main firms, has so far been published as preprint and must be submitted to peer review by the scientific community.
South Africa began offering booster doses to its general population last week, but before this measure came into force it had already begun to apply them to its health workers within a special program called “Together”.
Formulas used for vaccination anticovid in this country, which was the first to give the alert about the detection of omicron at the end of last November, are those of Pfizer Y NOT A WORD.
With some 3.4 million cumulative cases and nearly 91,000 deaths, South Africa is the epicenter of the pandemic in COVID-19 on the African continent.
The vaccination rate, however, is still low, with only about 27% of the population having the full schedule.
The current wave of infections driven by omicronAlthough it is causing a greater number of infections than other variants, it is leaving a significantly lower proportion of deaths and hospitalizations.